Fig. 2From: Natural killer cell-based immunotherapy for acute myeloid leukemiaStrategies of NK cell-based immunotherapy in activating the reconstitution of NK cells against AML. a Adoptive NK cell transfer. b CAR-NK cell therapy. c Antibodies targeting tumor associated antigens, BiKE and TriKE. d Antibodies targeting NK cell inhibitory receptors. e Cytokines. f Drugs with immunomodulatory function. BiKE bi-specific killer cell engager, CAR chimeric antigen receptor, HLA human leukocyte antigen, KIR killer immunoglobulin-like receptor, TriKE tri-specific killer cell engagerBack to article page